← Research library

Trekrezan in 103 inpatients with ongoing symptoms after COVID-19

Comparison in people · 2022

What was studied
103 hospital inpatients with ongoing symptoms after moderate or severe COVID-19. Background care plus Trekrezan: 53. Background care without adaptogens: 50.
Main finding
Mean MFI-20 fatigue scores fell from 44.5 to 31.9 with add-on Trekrezan and from 41.2 to 36.7 in the comparison group. Hospital stays averaged 11.4 vs 12.5 days.

MFI-20 fatigue score · 44.5 ± 13.9 to 31.9 ± 9.5 vs 41.2 ± 13.1 to 36.7 ± 6.4 · Days 8–10 · Table 2 lists p<0.001 without identifying the contrast in the table header.

Reported findings and study design

Open parallel-group hospital study. Patients were allocated by odd/even enrollment numbers. Assessments included MFI-20, lung diffusion capacity and oxygen saturation.

Population or model 103 hospital inpatients with ongoing symptoms after moderate or severe COVID-19. Background care plus Trekrezan: 53. Background care without adaptogens: 50.

Dose, route and schedule

Oral Trekrezan 600 mg on day 1, then 200 mg/day for seven days (2,000 mg total). The main assessment was at days 8–10.

Protocol source ↗ · Original journal PDF, methods and Table 2.

Results · Original journal PDF, methods and Table 2.
MeasureResultComparison, timing and statistics
MFI-20 fatigue score44.5 ± 13.9 to 31.9 ± 9.5 vs 41.2 ± 13.1 to 36.7 ± 6.4Days 8–10 · Table 2 lists p<0.001 without identifying the contrast in the table header.
Hospital stay11.4 ± 1.7 vs 12.5 ± 1.6 daysTable 2 reports p<0.001. The table does not specify the statistical test for this row.
Lung diffusion capacity (% predicted)64.7 to 68.7 vs 63.8 to 67.9Both groups improved by roughly four percentage points.

Source for these results ↗ · Reviewed 2026-11-15

Study limitations and source details

Study limitations

  • Open comparison with predictable odd/even assignment. The groups began with different mean fatigue scores. Both groups received other care.
  • This separate inpatient cohort used a different fatigue scale from the Zueva outpatient study.

Source details

Original journal PDF, methods and Table 2.

Sources checked

Citation

Human comparative studyFull text available

A. A. Zaitsev, N. A. Ternovskaya, E. A. Chelan, I. T. Kulagina, Y. A. Sidorov, V. I. Likhodiy. Trekrezan in 103 inpatients with ongoing symptoms after COVID-19 The Bulletin of Contemporary Clinical Medicine. 2022;15(1):26–33.

Study source ↗ · DOI 10.20969/VSKM.2022.15(1).26-33 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards